Approval · Notice of Compliance 18930 · 2017
INVOKAMET: Notice of Compliance 18930
Issued February 1, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 18930
- Date
- February 1, 2017
- Company
- Janssen Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the product monograph to include diabetic ketoacidosis (dka) in response to an advisement letter
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| INVOKAMET | Not yet assigned | — |
Medicinal ingredients
- METFORMIN HYDROCHLORIDE 850 MG per TAB
- CANAGLIFLOZIN 50 MG per TAB
- METFORMIN HYDROCHLORIDE 1,000 MG per TAB
- METFORMIN HYDROCHLORIDE 500 MG per TAB
- CANAGLIFLOZIN 150 MG per TAB